Abstract: A composition comprising: (i) a polymeric material (A) having a repeat unit of formula —(O-Ph)n-O-Ph-O-Ph-CO-Ph-??I and a repeat unit of formula —O-Ph-Ph-O-Ph-CO-Ph-??II wherein Ph represents a phenylene moiety and n represents 0 or 1; and (ii) a polymeric additive comprising one or more of: (a) a polycarbonate; and/or (b) a polymeric material (B) which includes a repeat unit of general formula wherein R1 and R2 independently represent a hydrogen atom or an optionally-substituted (preferably un-substituted) alkyl group, and R3 and R4 independently represent a hydrogen atom or an optionally-substituted alkyl group, an anhydride-containing moiety or an alkyloxycarbonyl-containing moiety.

Abstract: The present invention provides pregnancy associated plasma protein A2 (PAPP-A2), its nucleotide and amino acid sequences, antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described.

Abstract: A composite material comprising: i) one or more polymeric material having a repeat unit of formula —O-Ph-O-Ph-CO-Ph- (I) wherein Ph represents a phenylene moiety; and ii) one or more glass fibre; wherein said one or more polymeric material has a melt viscosity (MV) of more than 0.15 kNsm?2, but less than 0.65 kNsm?2, measured according to Example 1; wherein said one or more polymeric material a Melt Flow Index (MFI) that falls within the range 51% to 151% of the MFI calculated using the equation: log10(MFI)=1.929?2.408 (MV) wherein MV is the melt viscosity of said one or more polymeric material measured in kNsm?2 and according to Example 1, and wherein MFI is measured in g/10 mins according to Example 2.

Abstract: A composition comprising titanium dioxide, barium sulphate and/or zinc sulphide and one or more polymeric material selected from: i) a polymeric material (A) having a repeat unit of formula —O-Ph-O-Ph-CO-Ph- I and a repeat unit of formula —O-Ph-Ph-O-Ph-CO-Ph II wherein Ph represents a phenylene moiety; and/or ii) a polymeric material (B) having a repeat unit of formula —X-Ph-(X-Ph-)A-Ph-CO-Ph-III and a repeat unit of formula —X—Y—W-Ph-Z—W wherein Ph represents a phenylene moiety; each X independently represents an oxygen or sulphur atom; n represents an integer of 1 or 2; Y is selected from a phenylene moiety, a -Ph-Ph moiety and a naphthalenyl moiety; W is a carbonyl group, an oxygen or sulphur atom, Z is selected from —X-Ph-SO2-Ph- —X-Ph-SO2—Y—SO2-Ph- and —CO-Ph-.

Abstract: A composition comprising: (i) a polymeric material (A) having a repeat unit of formula (O-Ph)n-O-Ph-O-Ph-CO-Ph- ??I and a repeat unit of formula —O-Ph-Ph-O-Ph-CO-Ph- ??II wherein Ph represents a phenylene moiety and n represents 0 or 1; and (ii) a polymeric additive comprising one or more of. (a) a polycarbonate; and/or (b) a polymeric material (B) which includes a repeat unit of general formula wherein R? and R?? independently represent a hydrogen atom or an optionally-substituted (preferably un-substituted) alkyl group, and R3 and R4 independently represent a hydrogen atom or an optionally-substituted alkyl group, an anhydride-containing moiety or an alkyloxycarbonyl-containing moiety.

Abstract: The present invention relates to an isolated polynucleotide encoding at least a part of calmodulin and an isolated polypeptide comprising at least a part of a calmodulin protein, wherein the polynucleotide and the polypeptide comprise at least one mutation associated with a cardiac disorder. The present invention also relates to a method for determining whether an individual has an increased risk of contracting a cardiac disorder, a method for diagnosing a cardiac disorder, method for treatment of an individual having a cardiac disorder, method for identifying a compound, capable of enhancing the binding of calmodulin to ryanodine receptor 2 and use of such compound in a treatment of an individual having a cardiac disorder. The invention further provides a kit that can be used to detect specific mutations in calmodulin encoding genes.

Abstract: The present invention provides pregnancy associated plasma protein A2 (PAPP-A2), its nucleotide and amino acid sequences, antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described.

Abstract: The present invention provides pregnancy associated plasma protein A2 (PAPP-A2), its nucleotide and amino acid sequences, antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described.

Abstract: The present invention provides pregnancy associated plasma protein A2 (PAPP-A2), its nucleotide and amino acid sequences antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described.

Abstract: The present invention provides pregnancy associated plasma protein A2 (PAPP-A2), its nucleotide and amino acid sequences, antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described.

Abstract: The present invention provides a method of diagnosing Down's syndrome, acute coronary syndrome or pre-eclampsia, or a predisposition to any of them, by a method comprising measuring the level of the human PAPP-A/proMBP complex in a body fluid sample.

Abstract: Methods for screening for altered focal proliferation states in non-pregnant patients, which include detecting levels of pregnancy-associated plasma protein-A (PAPP-A), are described. Methods for identifying agents that alter the protease activity of PAPP-A, and pharmaceutical compositions and medical devices that include such agents also are described.

Abstract: Methods for screening for altered focal proliferation states in non-pregnant patients, which include detecting levels of pregnancy-associated plasma protein-A (PAPP-A) are described. Methods for identifying agents that alter the protease activity of PAPP-A, and pharmaceutical compositions and medical devices that include such agents are also described.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a new protein with homology to pregnancy-associated plasma protein-A (PAPP-A). We denote this protein PAPP-A2. The cDNA encoding PAPP-A2 was derived from human placenta.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a new protein with homology to pregnancy-associated plasma protein-A (PAPP-A). We denote this protein PAPP-A2. The cDNA encoding PAPP-A2 was derived from human placenta.